Show simple item record

dc.contributor.advisorDoymaz, Fuaten
dc.contributor.authorAbbasi Asbagh, Laykaen
dc.date.accessioned2014-07-22T13:51:31Z
dc.date.available2014-07-22T13:51:31Z
dc.date.issued2006en
dc.identifier.urihttp://hdl.handle.net/11147/3430
dc.descriptionThesis (Master)--Izmir Institute of Technology, Biotechnology, Izmir, 2006en
dc.descriptionIncludes bibliographical references (leaves: 51-64)en
dc.descriptionText in English; Abstract: Turkish and Englishen
dc.descriptionx, 64 leavesen
dc.description.abstractProstate cancer (CaP) is a common disease in aged men. Androgen deprivation therapy is the first line treatment for advanced disease. Following this therapy, within few months CaP cells become androgen independent in a few mounths. The mechanism responsible for development of androgen-independent cancer is not known. Evidences suggest that growth factors and cytokines including Interleukin.6 (IL-6) cast a main role in this mechanism. IL.6 is an important cytokine on CaP progression. Bisphosphonates inhibit the proliferation and induce the apoptosis of certain prostate cancer cell lines, in vitro. However, their mechanism of action is not clearly understood. One possible mechanism might be the IL-6 mediated pathway. This relation between zoledronic acid (ZA) and IL-6 hasn.t been studied.The objective of this study is to evaluate the cytotoxic and apoptotic effect of ZA on hormone independent CaP cell line (PC-3) and to understand the relation of underlying mechanism of ZA-mediated cytotoxicity and IL-6 expression. PC-3 cells were treated with different concentrations of ZA. Drug-mediated cytotoxicity and apoptosis were determined. IL-6 levels were measured from the supernatants of PC-3 cells at 24, 48, 72 hrs.Maximum cytotoxicity was achieved at 90 and 100 .M of ZA. ZA produced the classical DNA ladders on gel synonymous of apoptosis. The decrease in IL-6 secretion was found to be statistically significant compared to controls. The decreasing effect of ZA on IL-6 expression might suggest a new mechanism of action of ZA's antitumor activity. This outcome may offer a novel therapy that utilizes IL-6 antagonists along with ZA in CaP patients.en
dc.language.isoengen
dc.publisherIzmir Institute of Technologyen
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject.lcshProstate--Canceren
dc.subject.lcshProstate--Cancer--Treatmenten
dc.subject.lcshInterleukin-6en
dc.titleInvestigating the role of zoledronic acid on interleukin-6 cytokine expression in prostate cancer cell linesen
dc.typemasterThesisen
dc.contributor.departmentIzmir Institute of Technology. Biotechnology and Bioengineeringen
dc.relation.publicationcategoryTezen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record